This website is intended for people living with CF and their caregivers

Vertex medicines

If you live in England, Scotland or Wales

  • Please click here for KALYDECO® (ivacaftor) 13.4mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KALYDECO® (ivacaftor) 25mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KALYDECO® (ivacaftor) 50mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KALYDECO® (ivacaftor) 59.5mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KALYDECO® (ivacaftor) 75mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KALYDECO® (ivacaftor) 75mg tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KALYDECO® (ivacaftor) 150mg tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) 75mg/94mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) 100mg/125mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) 150mg/188mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) 100mg/125mg tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) 200mg/125mg tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for SYMKEVI®▼ (tezacaftor/ivacaftor) 50mg/75mg tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for SYMKEVI®▼ (tezacaftor/ivacaftor) 100mg/150mg tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KAFTRIO®▼ (ivacaftor/tezacaftor/elexacaftor) 60mg/40mg/80mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KAFTRIO®▼ (ivacaftor/tezacaftor/elexacaftor) 75mg/50mg/100mg granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KAFTRIO®▼ (ivacaftor/tezacaftor/elexacaftor) 37.5mg/25mg/50mg tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KAFTRIO®▼ (ivacaftor/tezacaftor/elexacaftor) 75mg/50mg/100mg tablets Package Leaflet or here for the Summary of Product Characteristics

 

If you live in Northern Ireland

  • Please click here for KALYDECO® (ivacaftor) granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KALYDECO® (ivacaftor) tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for SYMKEVI® (tezacaftor/ivacaftor) tablets Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KAFTRIO®▼ (ivacaftor/tezacaftor/elexacaftor) granules Package Leaflet or here for the Summary of Product Characteristics
  • Please click here for KAFTRIO®▼ (ivacaftor/tezacaftor/elexacaftor) tablets Package Leaflet or here for the Summary of Product Characteristics

 

ADVERSE EVENTS

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of these medicines. 

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience.